

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy ID6470


Provisional Stakeholder List

Patient/carer groupsServicePatient/carer groupsAll Wall CentreAmyloidosis UKAllied HArrythmia AllianceAllied HAtrial Fibrillation AssociationSosociationBritish Liver TrustBoard GCardiowascular Care PartnershipBritishGene PeopleCare CGenetic Alliance UKCell anHEART UKDepart and PuLiver4LifeDepart and PuSomerville FoundationMedicin RegulaSouth Asian Health FoundationNationaSpecialised Healthcare AllianceNationaHealthcare professional groupsNationaAssociation of Genetic Nurses and CounsellorsNHS CBritish Cardiovascular SocietyWelsh	es Inherited Metabolic Disease es Therapeutics and Toxicology lealth Professionals Federation ition of Renal Industries of Community Health Councils in
 National Heart and Lung Institute Primary Care Cardiovascular Society Royal College of General Practitioners Royal College of Nursing 	National Formulary uality Commission d Gene Therapy Catapult nent of Health, Social Services olic Safety for Northern Ireland are Improvement Scotland es and Healthcare products cory Agency I Association of Primary Care I Pharmacy Association I Services Division onfederation Medicines Consortium Government Health Specialised Services tee <u>omparator companies</u> cafamidis) <u>esearch groups</u> ion Foundation ne Heart Group

Provisional stakeholder list for the evaluation of vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy ID6470

Issue date: October 2024

© National Institute for Health and Care Excellence 2024. All rights reserved. 1 of 3



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 UK Clinical Pharmacy Association Vascular Society of Great Britain and Ireland 	 National Centre for Cardiovascular Preventions and Outcomes National Institute for Health Research
Others Department of Health and Social Care NHS England 	 <u>Associated Public Health groups</u> Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.


The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare

Provisional stakeholder list for the evaluation of vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy ID6470 Issue date: October 2024 © National Institute for Health and Care Excellence 2024. All rights reserved. 2 of 3



Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.